Prevalence Study of Iron Deficiency in Patients With Cancer (CARENFER ONCO)

Vifor

Status: Unknown

Conditions: Iron-deficiency

Treatments: Diagnostic Test: Iron deficiency testing

Study type: Interventional

Funder types: Industry

Identifiers

NCT03924271

CARENFER ONCO HEMATO

Details and patient eligibility

About

Despite its high prevalence, a recent study conducted by Prof. Cacoub (unpublished) on the french national health insurance database showed that iron deficiency was an underdiagnosed and under-treated co-morbidity. In inflammatory situations, especially during cancer, the measurement of the transferrin saturation factor is only performed in about 10% of cases whereas this measure is recommended in inflammatory situations including cancer (French Health High Authority 2011)

Enrollment: 1,200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient, male or female, over the age of 18
• Patient in an oncology department (any type of tumor, any type of treatment, initiated or not)
• Patient affiliated or beneficiary of a social security system
• Patient with written consent

Exclusion criteria

• Protected patient: major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
• Patient hospitalized without consent

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1,200 participants in 1 patient group

ONCOLOGY

Experimental group

Description:

Patient with a cancer

Treatment:

Diagnostic Test: Iron deficiency testing